SinoFresh HealthCare, Inc. Commences Program for the Clinical Evaluation of Their Nasal Spray in Treating and Preventing Sinusit
27 January 2011 - 3:39AM
SinoFresh® HealthCare, Inc., (Pink Sheets:SFSH) is pleased to
announce it has launched a program to initiate studies providing
additional data to evaluate the efficacy of SinoFresh Homeopathic
Antiseptic Nasal Spray in reducing the onset and duration of a
number of common illnesses such as sinusitis, common colds and flu.
SinoFresh HealthCare, Inc. anticipates that the initial study
designed to evaluate symptom relief for chronic sinusitis
sufferers, estimated to be as many as 37 million Americans, will
commence by the end of the Q2 2011.
William Wilferth, Chief Pharmacist and Vice President of R&D
states, "With our recent acquisition of SRS International,
SinoFresh is now in a position to initiate a program to fully
evaluate the impact of the product's use for a number of common
illnesses such as sinusitis, common colds and flu. SRS has
extensive expertise in the design, conduct and evaluation of
products like SinoFresh's Nasal Spray and will be able to develop
the data necessary for the company to inform users of the full
benefits of SinoFresh Nasal Spray use. We look forward to the
initiation of this program and the exciting potential it holds for
new and expanded uses of our premier product."
Wilferth continues, "We have been encouraged to take this next
important step by our nearly 10 years of input from both consumers
as well as the medical community citing strong anecdotal evidence
that the SinoFresh Homeopathic Antiseptic Nasal Spray has brought
significant relief to sinusitis sufferers. Numerous regular users
of the product have also reported to us a significant reduction in
the incidents of cold and flu infections. While we cannot make
these claims now, we have reason to be optimistic in evaluating the
regular use of a nasal antiseptic in reducing the onset and
duration of upper respiratory contracted illnesses."
"We are excited about initiating this program to support and
build the research and clinical database on our patented lead
product," stated David R. Olund, CEO. "We believe that success in
these clinical initiatives has the potential to expand product
usage, open additional markets and dramatically impact long term
shareholder value."
SinoFresh HealthCare, Inc. is a publicly traded
company (Pink Sheets:SFSH) based in Venice, Florida, that
manufactures and distributes nasal, oral and topical antiseptic
germ-killing products. SinoFresh products are marketed and
distributed globally through a network of strategic wholesale and
retail partners. SinoFresh Healthcare, Inc's, premier product,
SinoFresh Antiseptic Homeopathic Nasal spray has in laboratory
tests shown effective antiseptic capability against a variety of
pathogens such as MRSA, E-Coli, H1N1 and a broad range of other
viruses, molds, fungi and bacteria.
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Our
forward-looking statements express our current expectations or
forecasts of possible future results or events, including
projections of future performance, statements of management's plans
and objectives, future contracts, and forecasts of trends and other
matters. Forward-looking statements speak only as of the date of
this filing, and we undertake no obligation to update or revise
such statements to reflect new circumstances or unanticipated
events as they occur. You can identify these statements by the fact
that they do not relate strictly to historic or current facts and
often use words such as "anticipate", "estimate", "expect",
"believe", "will likely result", "outlook", "project" and other
words and expressions of similar meaning. No assurance can be given
that the results in any forward-looking statements will be achieved
and actual results could be affected by one or more factors, which
could cause them to differ materially. For these statements, we
claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act.
CONTACT: SinoFresh HealthCare Inc.
Investor Relations
941.375.8174 option 8